SELLAS is testing a drug to keep leukemia from coming back
GPS
an injection that trains the immune system
SLS009
a second drug, for patients other drugs fail
13 staff
others run its trials and make its drugs
A small New York company with no product on sale. It develops two drugs for acute myeloid leukemia, a fast-moving blood cancer, and pays partners to test and make them.
The company · 2 · What exactly does it sell?
It sells nothing yet; both drugs are still in trials
$0sales so far
$3.1Minterest earned on its cash in nine months
Until a drug is approved, its only income is interest on cash raised from selling shares. Every dollar it spends goes on trials and staff.
The company · 3 · How does it make money?
Selling shares pays for the trials
$134.7Mcash in September 2026
$22.4Mcash used in nine months
$85.1Mpaid in by warrant holders in 2026
If GPS is approved, SELLAS would sell it in the US and Europe and pay a royalty of a few percent to Memorial Sloan Kettering, where it was invented.
Is it a good business? · 4 · What gives it an edge?
Nothing is approved for its patients, if its trial works
Onuregthe one approved drug, for a first remission only
12 yearsUS protection from copies for an approved biologic
If GPS shows patients live longer, it would be the first drug approved to keep the disease away after a second round of treatment, protected for years by the rules.
Is it a good business? · 5 · What is the catch?
The proof so far is ten patients
10patients in the earlier GPS study
AbbVieits drugs are often kept going after remission
2026year some GPS patents run out
Listed rivals: ABBV · BMY · SNDX
The earlier study compared GPS patients with others who were not picked at random, so healthier patients may simply have done better.
Is it a good business? · 6 · What does its record show?
The trial finished counting, ten months later than registered
Trial127patients in the final trial
Count80deaths that trigger the final count, reached in October 2026
Shares203.9Mshares, from 74.0M at the end of 2024
The trial registry had expected the final count by December 2025. Meanwhile the company funded itself by issuing shares and lost an arbitration against its Chinese partner.
Is it a good business? · 7 · How much room is there to grow?
About 8,750 patients a year could use it, by its own count
22,720new US cases of this leukemia expected in 2026
8,750patients in a second remission, US, Europe and Japan
$129,238what Medicare paid per patient for Onureg in 2024
The 8,750 is the company's arithmetic from older reports. At Onureg's price it would be about $1.1B a year before any share of the market.
Is it a good business? · 8 · Who is in charge?
The founder has run it since 2012
Since 2012Angelos Stergiou, founder and chief executive
1.3%of shares owned by officers and directors
$676,000chief executive's salary in 2025
His bonus is tied to clinical and funding goals. Insiders own little of the company, and one director bought shares in 2025.
The story right now · 9 · Why does keeping a remission matter?
Most patients relapse, and relapse after a second remission usually kills
33.4%of patients alive five years after diagnosis
11,500US deaths expected in 2026
Treatment can clear the visible cancer, a remission, but a few hidden cells often survive and regrow it. A drug that stops that regrowth is what GPS is trying to be.
The story right now · 10 · Why does one result matter so much?
One trial result decides most of what the company is worth
Patients split in twoGPS or the usual care, at random.
Count the deathsThe result is read at 80.
Compare survivalLonger life on GPS, unlikely by chance?
Yes or noA miss leaves mostly cash.
A drug can only be sold once regulators approve it, and they look for a fair comparison. Before the result nobody outside the trial's independent committee knows which way it went.
The story right now · 11 · What changed lately?
The final count is in, and the result is due this month
28 Octthe 80th death, which triggers the final count
-53%the shares from their June high
28.3%of tradable shares sold short
Mixed quarter
The company promised the trial result in November 2026 and the first SLS009 data in new patients by the end of the year.
The story right now · 12 · What is everyone arguing about?
Will patients on GPS live longer?
Many investors think
It will probably work, and the slow pace of deaths shows it
We think
It may work, but the proof is thin and success is already in the price
The deaths are counted across both groups together, so their pace cannot say which group is doing better.
The price and our view · 13 · What is a share worth?
No single value here: the price already pays for success
0.6×if it works
5%kept if it fails
Multiples of the company's value when the bet was last struck, 16 Nov 2026.
We put no single value on a share, because there are no sales. The price pays about $1.39B more than the cash, roughly nine years of what an approved GPS might sell.
The price and our view · 14 · How could we be wrong?
One result, thin proof and more shares to come
One resultBiggest
A miss leaves mostly cash.
Thin proofShowing now
Ten patients in the earlier study.
Open trialWatch
Everyone knew who got GPS.
More sharesUnknown
A launch costs more than the cash.
Even a success may need new shares to pay for a sales force, which would shrink each holder's slice.
The price and our view · 15 · How will we know?
The trial result decides it, this month
Patients on GPS clearly live longer, with mild side effectsWe turn positive
Strong SLS009 data in newly diagnosed patientsGood sign
The trial misses its survival goalWe turn negative
NOV 2026-
The REGAL trial result, promised for November 2026. A drug developer's big tests are its trial results; this is the one that matters.
Our view moves on these trial events and on the price falling to about five times what the company owns, since we put no single value on a share here.
The price and our view · 16 · So, what do we think?
A coin flip whose winning side is already in the price
Priced for successthe kind of bet this is
NeutralLow conviction
SELLAS may have a first-of-its-kind leukemia drug, but the proof is thin and the price already pays for success, while a failure leaves about a twentieth in cash. Neutral.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
SELLAS is a 13-person company in New York that develops cancer drugs and pays others to run its trials and make them. GPS, licensed from Memorial Sloan Kettering Cancer Center, is its lead. The second, SLS009, licensed from China's GenFleet, is a drug given by drip alongside standard leukemia drugs.
Its future customers would be leukemia doctors and the insurers who pay them. Today it has none, because nothing is approved.
How it makes money
It does not make money yet. It earns only interest on its cash and spends about $30M a year on trials and staff, paid for by selling shares. If GPS is approved, SELLAS would sell it in the US and Europe and pay a royalty of a few percent to Memorial Sloan Kettering; a Chinese partner holds the rights in Greater China.
Growth and profit
What growth costs
With no sales there is nothing to compare costs against. Spending fell in 2025 after the trial finished enrolling, then rose 56% in the first nine months of 2026 as the company prepares to apply for approval.
Why it wins
The evidence
Nothing protects it yet. If the trial succeeds, GPS would be the first drug approved to keep this leukemia away after a second treatment, and US law would protect it from copies for years as a rare-disease drug made from proteins. Some patents end in 2026, so the rules, not patents, would protect it.
The need is real: only about one patient in three is alive five years after diagnosis, and the one approved drug for keeping the disease away is labelled only for the first remission.
Who could beat it
The rivals in full
Doctors already keep many patients on the drugs that put them into remission, AbbVie's venetoclax and azacitidine, and send fit patients to a stem cell transplant, the only proven cure. Newer drugs such as Syndax's Revuforj treat relapse in patients with certain gene changes.
Each rival
AbbVie's venetoclax with azacitidine, continued after remissionABBV
Maintenance by continuing the salvage drugs, the commonest part of REGAL's control arm.
BMS's oral azacitidine, OnuregBMY
Approved maintenance in a first remission; could be used or studied in a second.
Syndax's menin inhibitor RevuforjSNDX
Treatment of relapse in NPM1 and KMT2A subtypes, and a candidate for maintenance in them.
Allogeneic stem cell transplantnot listed
The only proven cure, for patients fit enough; REGAL excludes them.
How big it could get
The market and who has signed
The market
SELLAS counts about 8,750 patients a year in the US, the largest European markets and Japan who reach a second remission. That figure is the company's own arithmetic from older reports, and not all of those patients would be eligible.
For scale, Medicare paid about $129,000 a patient for Bristol Myers Squibb's Onureg in 2024, across 665 patients. At that price, 8,750 patients would be about $1.1B a year before any share of the market is assumed.
Who runs it
Leaders, pay and the cash
Who runs it
Angelos Stergiou, a doctor, founded the company in 2012 and has run it since; he was paid a $676,000 salary and a $390,390 bonus in 2025, the bonus tied to clinical and funding goals. Officers and directors together own about 1.3% of the shares.
What they did with the money
SELLAS has funded itself by selling shares and warrants, the right to buy shares later at a set price. The share count went from 74 million at the end of 2024 to 204 million in November 2026. In July 2026 it lost an arbitration against its Chinese partner. A $150M programme to sell more shares is in place and unused.
The last report
The latest report
Loss of $10.1M as trial spending rises; cash at $134.7M
What it did to the thesis Mixed quarter
It changed nothing about the case. The cash covers years of trials at this pace, so the company will not be forced to sell shares before the result, but the quarter held no new evidence on whether GPS works.
The report
In the quarter to September 2026 SELLAS lost $10.1M, as research spending rose to $7.0M while it prepares to apply for approval. It ended the quarter with $134.7M of cash after warrant holders paid in $85.1M this year, and no debt.
It said the trial result would come in November and that the first SLS009 data in newly diagnosed patients would come by the end of the year.
What's happening now
The background
The 80th death in the trial was announced on 28 October 2026, which starts the final count, and the result is promised for November. The shares fell 15% that day and are 53% below their June high, after law firms questioned the timing of the company's statements. More than a quarter of the shares that trade are sold short.
The next test is the result itself: whether patients given GPS lived meaningfully longer than those on standard care.
Where we disagree
Both sides in full
The market
The trial will probably work, and the slow deaths show it.
We believe
It may work, but the evidence is thin and success is already in the price.
The argument
Every analyst covering it rates it a buy, and many holders read the slow pace of deaths in the trial as a sign that GPS patients are living longer.
We cannot read it that way: the deaths are counted across both groups together, and the earlier evidence is ten patients compared with others who were not chosen at random. The trial could well succeed, but the price already pays for that.
What it's worth
How we value it
No fair value: SELLAS has no sales, has never made a profit, and its value turns on one trial result not yet public, so a value built on earnings would rest on a guess; the bet prices it instead.
The bet
If the trial works and GPS is approved, a reasonable result is about 1,160 patients a year, nearly twice Onureg's Medicare patients, and about $150M of sales. At six times sales that is worth about $900M, less than today's market value, so even success pays little from here.
If the trial fails, holders keep the cash left after a couple of years of SLS009 trials, about a twentieth of today's value. The bet is priced for success.
The bet
Seen as a bet
If the trial works and GPS is approved, a reasonable result is about 1,160 patients a year, nearly twice Onureg's Medicare patients, and about $150M of sales. At six times sales that is worth about $900M, less than today's market value, so even success pays little from here.
If the trial fails, holders keep the cash left after a couple of years of SLS009 trials, about a twentieth of today's value. The bet is priced for success.
What could go wrong
Every risk
The risks
One result decides it
If the trial misses, most of the value goes, leaving cash and the second drug.
Thin earlier evidence
The case rests on ten patients and studies with no fair comparison group.
Open-label trial
Doctors and patients knew who got GPS, which regulators may weigh against a small benefit.
More shares
Launching a drug costs far more than the cash, so new shares are likely even after success.
Delays
The final count came about ten months later than the trial registry had estimated.
What we still do not know
What survival gain the trial was designed to show, and how likely it was to show it.
Whether insurers would pay for GPS like a cancer drug or like a cheaper vaccine.
Whether SLS009 works well enough in newly diagnosed patients to carry the company if GPS fails.
What changes our view
Every route to a new view
Every route to a new view
→ Attractive
The trial shows patients on GPS live longer, by a margin unlikely to be chance. SELLAS applies for approval with the FDA's agreement.
→ Unattractive
The trial misses its survival goal.
→ Attractive
Before the result, market value falls to five times book value, what it owns minus what it owes.
The next test
It supports the case if
A significant survival gain, a hazard ratio well below 0.7 and leukemia-free survival moving the same way, with mild side effects.
It pressures the case if
No significant survival gain, a delay past December, or a result framed only on subgroups.
We would also be wrong if
The FDA will not accept an application based on an open-label trial.
SELLAS sells more than 40 million new shares before any approval.
SLS009 beats standard drugs in its randomised trial in newly diagnosed patients.
The verdict
Scores and how we weighed it
The scores
Growthnot scored
Business quality
2 of 4
Financial position
3 of 4
Execution record
2 of 4
Per share capture
1 of 4
Potential
2 of 4
Risk profile
2 of 4
Valuation
2 of 4
Evidence quality
2 of 4
How we weighed it
ValueNegative
No fair value is drawn because there are no sales; the price pays well above the cash for drugs not yet shown to work.
BusinessNegative
Nothing is approved and the company has never sold a product; a moat appears only after a positive trial and approval.
GrowthMixed
An approved GPS could reach thousands of patients a year with nothing else approved in its setting, but no sales exist today.
RisksNegative
One open-label trial decides most of the value, the earlier evidence is small, and new shares will be needed to launch.
RivalsMixed
No approved drug keeps a second remission, but doctors already continue venetoclax and azacitidine and send fit patients to transplant.
The groupMixed
Small biotech shares move on their own trial news; the group's mood matters less than the readout.
Latest newsMixed
The final count was reached and the result promised this month, but it arrived late and the shares fell on it.